JPMorgan analyst Anupam Rama said he is adding Sarepta's micro-dystrophin program to his model following the company's R&D day, reiterating his earlier call that the update "vastly exceeded" expectations. He estimates peak sales of $4B-$5B for the micro-dystrophin program, adding that the breadth of the pipeline highlighted at the R&D day leads him to believe Sarepta has the potential to enter the ranks of the "emerging large-caps" in the next 12-24 months. Rama raised his price target on Sarepta to $205 from $87 and keeps an Overweight rating on the shares.